Zirtec

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zirtec

Property Description
Active ingredient Cetirizine Hydrochloride
Form Oral (Tablet, Syrup, Oral Solution)
Pharmacological Class Second-Generation Antihistamine, H₁-Receptor Antagonist
Common Use Relief of allergic symptoms
Origin Synthetic (Piperazine derivative)

What is Zirtec and What Type of Medicine is It?

Zirtec is a widely known trade name for a medicinal preparation whose active component is Cetirizine Hydrochloride, classified within the medical discipline as an antihistamine used for the systemic management of allergic conditions. It belongs to the Second-Generation Antihistamine (SGAH) class, functioning specifically as a selective H1-Receptor Antagonist. This distinction confirms the drug's pharmacological role in interfering with the chemical processes initiated by allergens. Cetirizine is an orally active substance clinically recognized for its rapid onset of effect, and in many regions, Zirtec is available as an Over-the-Counter (OTC) option, offering broad patient accessibility.


Composition, Origin, and Available Forms

The therapeutic action of Zirtec is derived solely from Cetirizine Hydrochloride, establishing it as a single-ingredient product. This compound is synthetic, structurally related to the first-generation antihistamine Hydroxyzine, yet engineered for greater specificity. It is prepared for systemic effect via the oral route of administration. Zirtec is offered in various user-friendly dosage forms, including film-coated tablets and liquid forms like syrups and oral solutions. The availability of a palatable oral solution often targets pediatric patients and individuals who may have difficulty swallowing solid medications.


What is the General Purpose of This Antihistamine?

The general purpose of Zirtec is to mitigate the unpleasant physical symptoms that occur when the body releases the chemical mediator histamine in response to an allergen, such as during seasonal allergy flare-ups. By binding to and blocking the histamine receptors, the drug provides systemic relief from allergic symptoms. A key characteristic of its second-generation status is its low central nervous system (CNS) penetration, which allows the medication to control peripheral symptoms like itching and swelling while minimizing the sedating effects often associated with older antihistamine medications. This characteristic supports its positioning for use during daytime activities.

Regulatory References

  1. Cetirizine Hydrochloride FDA Labeling Information
  2. Second-Generation Antihistamine (SGAH) - SmPC
  3. MedlinePlus Drug Information on Cetirizine
  4. film-coated tablets - SmPC

What side effects are possible with Zirtec?

The safety profile of Cetirizine Hydrochloride, the active ingredient in Zirtec, is established through formal regulatory classifications that categorize adverse reactions by their expected frequency and the affected body system.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on incidence rates found in clinical studies and post-marketing surveillance, consistent with official regulatory frequency bands:

  • Common: Reactions observed in 1% to 10% of patients, primarily affecting the nervous and respiratory systems, include somnolence (drowsiness), headache, fatigue, dry mouth, pharyngitis, and rhinitis.
  • Uncommon: Effects occurring in 0.1% to 1% of patients, such as diarrhea, pruritus (itching), rash, and agitation.
  • Rare: Reactions occurring in 0.01% to 0.1% of patients, including tachycardia (fast heart rate), oedema (swelling), convulsions, and liver function abnormalities.

Serious Adverse Reactions and Safety Restrictions

Regulatory documentation outlines rare but serious safety events. These include severe hypersensitivity reactions, such as anaphylactic shock and angioedema, as well as reports of hepatitis linked to significant liver function abnormalities.

Usage of this medicine is subject to specific regulatory limitations. It is contraindicated in individuals with severe renal impairment (creatinine clearance less than 10 ml/min) due to the drug's primary route of excretion. Specific safety considerations also apply to older adults and patients with predisposing factors for urinary retention.

Somnolence is a noted safety pattern that is often observed more frequently at the beginning of treatment. Furthermore, official sources have documented reports of intense pruritus (itching) upon stopping long-term use of the medication.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Cetirizine Hydrochloride (Zirtec) is documented in regulatory prescribing information, defining both the expected clinical presentations and the mandated emergency actions.

Documented Overdose Manifestations

Official regulatory sources report that manifestations commonly involve the Central Nervous System (CNS), with somnolence (drowsiness) being the most frequently observed sign in adults. However, in children, a phase of agitation or restlessness may be noted prior to the onset of sedation. Other symptoms documented across physiological systems include tachycardia (fast heart rate), headache, dry mouth, tremor, and diarrhea.

Rare but severe outcomes listed in the official profile include seizures and progression to coma. These severe manifestations, particularly those affecting the CNS or heart, necessitate immediate professional evaluation.

Required Emergency Action

Government guidance explicitly mandates that individuals must seek immediate medical attention or contact a Poison Control Center right away if an overdose is suspected. Urgent medical help is required if the affected individual has collapsed, is seizing, has difficulty breathing, or cannot be awakened, which necessitates an immediate call to emergency services (e.g., 911 in the U.S.).

Management and Antidote Information

Official documents consistently state that no known specific antidote exists for Cetirizine overdose. Therefore, the required clinical approach is limited to symptomatic and supportive treatment. Furthermore, official regulatory information notes that dialysis is not effective for drug removal in an overdose situation. The profile also highlights that the pediatric population requires caution due to a different initial presentation, and the elderly may be affected by the drug’s prolonged elimination time.

Therapeutic Uses of Zirtec

What Zirtec Treats: Main Uses and Benefits

The primary therapeutic focus of this medication is to provide supportive relief for symptoms related to allergic conditions.

The therapeutic use of this medication is relevant for easing symptoms related to heightened physiological activity caused by allergies. This includes common conditions like seasonal allergic rhinitis (hay fever), perennial allergic rhinitis (year-round allergies), and chronic idiopathic urticaria (hives).

The medication helps address symptom clusters that may become intense or disruptive, such as sneezing, runny nose, itching of the nose and throat, and the itching and watering of the eyes. For skin manifestations, it is applied to manage the pronounced itching and redness associated with hives.

“This support for chronic and seasonal phases is important because it helps maintain a sense of stability when symptoms interfere with routine activities.”

The medication is commonly used across conditions presenting with recurrent or episodic manifestations, offering symptomatic assistance that helps patients cope more steadily with temporary functional strain.

Quick Fact: Symptom Management for Skin Reactions
Supports the management of pruritus (generalized itching) and the appearance of welts (swelling) associated with hives.

Regulatory References

  1. NIH MedlinePlus overview on Cetirizine

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Zirtec

Official regulatory documents define the eligible population for Zirtec (Cetirizine) through age restrictions, contraindications, and conditional use requirements.

Absolute Contraindications (Must Not Use)

Zirtec is formally contraindicated for patients with a known hypersensitivity or allergy to the active substance, to the related compound Hydroxyzine, or to any Piperazine derivatives. It must also be avoided by individuals with end-stage renal disease, typically defined as a Creatinine Clearance below 10 mL/min.

Age-Related Eligibility

Age Group Eligibility Status
Infants (< 6 months) Use is not established (efficacy and safety insufficient).
Children (6 months to 5 years) Eligible for liquid forms (syrup/oral solution) for approved conditions.
Children (ge 6 years) & Adults Eligible for both tablet and liquid forms.

Restricted and Conditional Use

Patients with moderate to severe renal impairment (CrCl <50 mL/min) require mandatory dose reduction. Use in older adults (geriatric patients) must also consider potential age-related reductions in kidney function, often necessitating a lower dose. Furthermore, caution is recommended for pregnant and lactating women, as well as those with a predisposition to urinary retention or a history of epilepsy or convulsions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Zirtec (Cetirizine Hydrochloride) focuses on specific pharmacokinetic and pharmacodynamic interactions documented in prescribing labels.

Pharmacodynamic and Substance Interactions

Interacting Substance Category Regulatory Statement Outcome Classification
Alcohol (Ethanol) & CNS Depressants Co-administration may result in an additive central nervous system (CNS) effect. Precaution advised; risk of reduction in alertness or impairment of performance.
Food Decreases the rate of absorption, but the extent of absorption (total exposure) is not reduced. Non-significant timing effect.

Pharmacokinetic Drug Interactions

While studies with various medicines, including pseudoephedrine, ketoconazole, erythromycin, and azithromycin, found no clinically significant pharmacokinetic interactions, a specific clearance alteration is documented.

Co-administration with Theophylline (at a 400 mg once daily dose) results in a 16% decrease in the clearance of cetirizine. This is a formal pharmacokinetic finding that increases cetirizine's systemic exposure.

Population-Specific Interaction Notes

Due to Zirtec’s primary renal excretion, the potential for accumulation and heightened interaction effects must be considered in patients with moderate to severe renal impairment. Dose adjustment is required under these conditions. Consideration for hepatic impairment is only necessary if concomitant renal impairment is present.

Mechanism of Action

Pharmacodynamic Mechanism of Cetirizine

Cetirizine, a compound classified as an antihistamine, functions by specifically targeting and modifying pathways associated with histamine release and receptor activity.

Targeted Peripheral H1 Receptor Blockade

The primary molecular action involves cetirizine acting as a selective competitive antagonist of the peripheral Histamine H1 receptor. It achieves this by binding to the H1 receptors, thereby preventing the naturally released inflammatory mediator, histamine, from activating them. This targeted interaction modifies the early molecular steps that initiate the histamine cascade, resulting in a dampening of downstream signaling from excessive histamine activity.

Localized Pathway Activity

This mechanism is further defined by its limited ability to cross the blood-brain barrier (BBB). Consequently, cetirizine's H1 receptor blockade is largely confined to the body's periphery. By concentrating its activity on peripheral pathways, it avoids significant interference with central nervous system functions, which results in a modified activity pattern within targeted peripheral systems and helps to limit the impact of H1 receptor blockade on the central nervous system.

Dosage and Administration Information

The administration of Zirtec (Cetirizine Hydrochloride) is exclusively by the oral route, utilizing dosage forms such as film-coated tablets, chewable tablets, and liquid solutions. The primary dosing pattern for adults and adolescents aged 12 years and older is a standardized 10 mg once daily regimen, which represents the maximum recommended dose in a 24-hour period. For certain older adult populations or less severe conditions, a starting dose of 5 mg once daily may be utilized.


The medication is taken on a once-daily schedule. Instructions state that it can be administered with or without food, allowing for usage independent of meal schedules. For pediatric patients between 6 and 11 years, the daily dose may be given as a single 10 mg dose or as a divided dose of 5 mg taken twice daily.


Administration requires attention to form-specific guidelines. Liquid oral solutions must be accurately measured using a calibrated device provided with the product. Labeling specifies that chewable tablets must be thoroughly chewed before swallowing, while non-chewable forms should be swallowed whole. A critical procedural element involves dose adjustment based on physiological status: for adult patients with moderate to severe renal (kidney) impairment, the daily dose is reduced to 5 mg once daily to align with prescribed safety constraints. This dose modification for impaired function defines a key constraint in the usage protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zirtec

This section summarizes the structure of the official research and the types of findings reported in clinical trials for Zirtec, based on authoritative governmental and peer-reviewed sources. The summary describes the research structure and findings without offering any advice or interpretation.


Evidence for Symptoms of Seasonal Allergic Rhinitis (Hay Fever)

The research base is structured around short-term Randomized Controlled Trials (RCTs) used to explore conditions such as seasonal allergic rhinitis, commonly known as hay fever. These studies were used in research exploring how symptoms change over time by monitoring patient groups who received cetirizine compared to those receiving an inactive treatment (placebo) or another active medication.

In these trials, researchers primarily monitored patient-reported outcomes describing perceived discomfort related to physical discomfort, such as sneezing, runny nose, and itching of the eyes and nose. These outcomes were tracked using Total Symptom Scores (TSS). Research monitored symptom scores, and findings describe patterns observed in the studies when compared to a placebo or comparator group. The results apply only to the populations studied and the settings of the short-term trials. Limited information exists for long-term outcomes, meaning the evidence for continuous use across an entire multi-month allergy season is less established.


Evidence for Chronic Hives (Chronic Idiopathic Urticaria)

Zirtec was evaluated in research exploring the symptoms associated with Chronic Idiopathic Urticaria (CIU), such as pruritus (itching) and wheals (welts). The main outcomes related to physical discomfort were assessed using the Urticaria Activity Score (UAS), which combines the patient-reported severity of itching and the physical appearance of the wheals. Research monitored the UAS, and findings describe patterns observed when the treatment group was compared to the placebo group. The overall evidence quality varies across studies, partly because sample sizes were modest in some pivotal CIU trials. Furthermore, there is limited information for long-term outcomes, providing less context on the continuous observation of this chronic condition over multiple years.


Research in Specific and Special Populations

Zirtec was evaluated in studies involving children (pediatric patients), and research describes findings related to children as young as 2 years old, depending on the specific regulatory area. Research describes patterns observed in studies that included older adults. However, the results apply only to the populations studied, and data for certain complex or special populations remain insufficient across the generalized evidence base.


What Is Still Uncertain: Evidence Gaps and Inconsistency

Comparative evidence is limited, particularly when assessing Zirtec against other available second-generation antihistamines using identical clinical trial protocols. Findings were mixed when studies explored the use of doses exceeding the standard recommended amount, suggesting that subgroup findings are uncertain. Overall, there is limited information for long-term outcomes across all indications. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References Cetirizine Hydrochloride Tablet Labeling and Monograph (Official Regulatory Document)

Frequently Asked Questions (FAQ)

Common questions about Zirtec (FAQ)

Q: Is Zirtec the same kind of medicine as Benadryl?

Zirtec is formally classified as a Second-Generation Antihistamine (SGAH), while Benadryl (diphenhydramine) is a First-Generation Antihistamine.

The classification of Zirtec is based on its mechanism of action, which primarily targets peripheral receptors in the body. This targeted activity results in low central nervous system (CNS) penetration, distinguishing it from older antihistamine medicines.

Q: How fast does Zirtec start working after you take it?

The active ingredient in Zirtec is clinically recognized for its rapid onset of effect.

Official documentation reports that the maximum levels of the drug in the blood are generally measured within approximately one hour after taking a dose.

Q: How long do the effects of Zirtec usually last?

Zirtec is designed for a once-daily schedule for adult use, according to official product information.

This dosing regimen is consistent with an established duration of action to support a 24-hour interval.

Q: Is it common to feel tired the morning after taking Zirtec?

Drowsiness (somnolence) and fatigue are categorized as Common adverse reactions.

These effects are noted in official sources as being observed in 1% to 10% of patients in clinical studies. Official information indicates that the occurrence of drowsiness may be observed more frequently when treatment is first initiated.

Q: Do studies suggest Zirtec is safe for long-term daily use?

Research overviews indicate that evidence for the continuous use across long periods is less established compared to short-term use.

Furthermore, post-marketing safety data includes reports of intense itching (pruritus) that has occurred when patients stop taking the medication after using it daily for long periods.

Q: If Zirtec is taken for several months, does stopping it cause any rebound effects?

Post-marketing safety surveillance documents reports of intense itching (pruritus) that may occur within a few days of stopping Zirtec after long-term daily use.

This reported effect, which is not an allergic reaction, has been observed in patients who used the drug continuously for months or years.

Q: What is the difference between Zirtec and Zirtec-D?

Zirtec contains only the single active ingredient, Cetirizine Hydrochloride, which is the antihistamine component.

Combination products such as Zirtec-D include an additional active ingredient, most commonly a decongestant like pseudoephedrine. The addition of a decongestant makes Zirtec-D a different type of medicine.

Q: Can Zirtec be taken with a cold or flu medicine?

Regulatory documents advise caution when considering Zirtec alongside other medicines, including cold and flu products, that may cause drowsiness.

Combining Zirtec with other central nervous system (CNS) depressants may result in an additive CNS effect, which could further reduce alertness or impair performance.

Q: Does Zirtec lose its effectiveness if you take it every day?

Official clinical literature suggests that the medication generally maintains its effectiveness over extended periods of daily use.

It is not commonly associated with the development of tolerance, or tachyphylaxis, which is the decreased response to a drug after continued use.

Q: Why is Zirtec sometimes recommended for chronic hives?

Zirtec has an official regulatory indication for treating the uncomplicated skin manifestations of Chronic Idiopathic Urticaria (CIU), which refers to chronic hives.

The clinical research supporting this use monitored patient discomfort and physical signs, noting reductions in symptoms such as itching (pruritus) and swelling (wheals).

Q: What types of foods or drinks should you be careful about when taking Zirtec?

Regulatory documentation specifically advises caution regarding the co-administration of Zirtec with alcohol (ethanol).

This combination may result in an additive central nervous system (CNS) effect, which can lead to reduced alertness. Regarding food, taking Zirtec with food is described as decreasing the rate of absorption, but the total amount of drug absorbed by the body is not reduced.

Q: Can people who have liver problems use Zirtec?

Official documentation states that consideration must be given for patients with a history of liver problems.

While a dose reduction may be mentioned, this is only explicitly described in regulatory texts when liver problems are present alongside reduced kidney function (renal impairment).

Q: Is there any risk of becoming dependent on Zirtec?

Official drug information sources and regulatory documents do not list dependence or addiction as a risk associated with Zirtec.

The primary focus of safety warnings related to stopping the medication is the potential for intense itching (pruritus) that has been reported following long-term use.

Q: What does it mean that Zirtec is 'non-drowsy' for some people?

The description 'non-drowsy' relates to Zirtec’s classification as a second-generation antihistamine.

This class of medicine has low central nervous system (CNS) penetration, meaning it is designed to minimize the sedating effects that older antihistamines are known for while still controlling peripheral allergic symptoms.

Q: Are there any specific safety warnings about Zirtec for older adults?

Official safety considerations apply to older adults because of the potential for age-related reductions in kidney function. This change may necessitate a reduced daily dose.

Caution is also recommended in patients who may have a predisposition to urinary retention, which is the inability to fully empty the bladder.

Q: Can Zirtec affect my performance while driving or operating machinery?

Regulatory documents explicitly advise that due caution should be exercised when driving a car or operating potentially dangerous machinery.

This warning is in place because the occurrence of drowsiness (somnolence) has been reported as a common side effect in clinical trials.

Q: What is the typical age range for children allowed to use Zirtec?

Official documentation describes eligibility for children beginning at 6 months of age.

Children between 6 months and 5 years are eligible for liquid forms of the medicine, and those 6 years and older are eligible for both liquid and tablet forms. Use in infants under 6 months is not established.

Q: Is Zirtec safe to take if I have high blood pressure?

Official documents for single-ingredient Zirtec (cetirizine only) generally describe it as having no effect on blood pressure.

However, it is important to distinguish this from combination products like Zirtec-D, which include a decongestant that may carry specific warnings regarding high blood pressure.

Q: Do people report feeling 'foggy' or having trouble concentrating while taking Zirtec?

The most common adverse reaction reported is drowsiness (somnolence).

While the specific terms 'foggy' or 'trouble concentrating' are not listed in the most common side effects, regulatory documents caution that the risk of reduced alertness or impairment of performance is present, particularly when Zirtec is taken with other substances.

Q: What research evidence supports the use of Zirtec for indoor allergies?

Zirtec has an official indication for the relief of symptoms associated with perennial allergic rhinitis.

This medical term refers to allergies that persist year-round, which typically include reactions to common indoor allergens like dust mites, animal dander, and molds.

Q: Why do some people experience dry mouth while using Zirtec?

Dry mouth is classified as a Common adverse reaction, reported in 1, % to 10, % of patients in clinical trials.

Although Zirtec is recognized for having low anticholinergic activity, which is the mechanism usually responsible for dry mouth, official regulatory documents confirm that this side effect is a reported finding.

Q: Is it okay to take Zirtec right before bed?

Official instructions indicate that the drug is taken on a once-daily schedule and can be administered with or without food, without specifying a required time of day.

However, because drowsiness (somnolence) is a common side effect, some individuals may choose to take Zirtec in the evening.

Q: What is the risk classification of Zirtec?

The formal safety profile of Zirtec is established through a defined list of adverse reactions classified by frequency and a list of contraindications, such as for individuals with severe kidney impairment.

Official documents also include specific cautions and considerations for use in populations such as pregnant and lactating women.

Q: Does Zirtec have any known interactions with herbal supplements?

Official regulatory documents advise patients to inform their healthcare provider about any prescription, nonprescription medicines, vitamins, and herbal products they are taking.

This information allows the doctor to monitor the patient carefully for potential side effects or altered drug effects.

Q: What official sources describe the expected duration of Zirtec's effect?

Official regulatory documents from sources like the FDA and EMA describe the expected duration of effect indirectly through the established dosing schedule.

They state that the primary dosing pattern for adults is once daily, which reflects the duration of action intended for the medication.

Q: Can Zirtec be used to prevent an allergic reaction from happening?

The general purpose of Zirtec is to mitigate or relieve symptoms that occur due to an allergic response.

The drug’s primary action is to block the effects of histamine after it is released by the body, meaning it functions as a mitigating agent rather than a primary preventative agent against the initial allergic reaction.

Q: Does Zirtec have an official indication for treating motion sickness?

Official regulatory indications for Zirtec include the relief of symptoms associated with seasonal and perennial allergic rhinitis (hay fever and indoor allergies), and chronic hives.

Motion sickness is not listed in the official documents as an approved indication for the use of Zirtec.

Q: Are there any documented cases of Zirtec affecting sleep patterns?

Adverse reactions affecting the nervous system are documented in official safety surveillance.

While drowsiness (somnolence) is common, post-marketing reports also include cases of anxiety and trouble sleeping (insomnia), suggesting that sleep patterns may be affected in some individuals.

Q: Is Zirtec available in different strengths (mg)?

Yes, Zirtec is available in different strengths for oral administration, depending on the dosage form.

The medication is made available in different measured strengths for oral administration. Official regulatory texts describe the use of both 10, mg and 5, mg strengths.

How should Zirtec be stored and disposed of?

How to Store and Dispose of Zyrtec

Zyrtec (cetirizine hydrochloride) must be stored at Controlled Room Temperature (CRT), which is 20°C to 25°C (68°F to 77°F). It is essential to avoid excessive heat above 40^circC and, for specific forms like liquid-filled capsules and orally disintegrating tablets, to avoid high humidity and protect from light.

Packaging and Safety

The product must be stored in its original container, and usage should be avoided if tamper-evident seals are broken. All forms of Zyrtec must be kept out of the sight and reach of children.

Disposal

Official labeling does not provide specific instructions for non-household disposal of unused product. Disposal should align with local environmental regulations for discarding expired or unwanted medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zirtec found in:

A-Z Index: